Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Deferred Tax: 2016-2020

Historic Long-Term Deferred Tax for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Dec 2020 value amounting to $62.0 million.

  • Lineage Cell Therapeutics' Long-Term Deferred Tax rose 10.15% to $62.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $62.0 million, marking a year-over-year increase of 10.15%. This contributed to the annual value of $62.0 million for FY2020, which is 10.15% up from last year.
  • As of FY2020, Lineage Cell Therapeutics' Long-Term Deferred Tax stood at $62.0 million, which was up 10.15% from $56.3 million recorded in FY2019.
  • Lineage Cell Therapeutics' Long-Term Deferred Tax's 5-year high stood at $62.0 million during FY2020, with a 5-year trough of $49,213 in FY2016.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $56.3 million (2019), whereas its average is $52.3 million.
  • In the last 5 years, Lineage Cell Therapeutics' Long-Term Deferred Tax spiked by 82,489.97% in 2017 and then decreased by 5.24% in 2018.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Long-Term Deferred Tax stood at $49,213 in 2016, then surged by 82,489.97% to $40.6 million in 2017, then declined by 5.24% to $38.5 million in 2018, then surged by 46.12% to $56.3 million in 2019, then rose by 10.15% to $62.0 million in 2020.